Explore Business Standard
The government has approved Bharat Biotech's intranasal Covid-19 vaccine, iNCOVACC (BBV154), as a booster dose for those above 18 years of age. How does this needle-free vaccine work and how different is it from the existing ones? To get the answers, Business Standard spoke to Dr Gagandeep Kang, virologist and professor at the Christian Medical College, Vellore. Watch the video for more
In this interview to Nivedita Mookerji of Business Standard, Dr Amita Gupta, who's also a professor of infectious diseases at the Johns Hopkins School of Medicine, talks about 2022 being more of the same, how the year will have more waves and that Covid will never go away. She explains how the Johns Hopkins Covid dashboard became a household name, while highlighting the weakness in the health infrastructure and data systems in many countries including in India. According to Dr Gupta, Covid19 should be seen as a wakeup call to improve things.
AIIMS director Randeep Guleria said that as the number of recovered patients rises, clinics have to be developed to deal with the treatment of symptoms which persist beyond the disease. He said there was now a better understanding of post-Covid acute syndrome which can continue 8 to 12 weeks and long Covid which can occur if symptoms continue beyond 12 weeks. Watch this video to understand the post-Covid complications and treatment options as explained by the AIIMS chief.
Coronavirus updates: A decision on the next phase of Covid-19 vaccination was taken at a meeting of the Union Cabinet under the chairmanship of Prime Minister Narendra Modi on February 24. Who is eligible in the second round of vaccination and what are the charges, if any? Will there be a choice in the vaccine? The video answers all your queries in a quick time.
Serum Institute of India CEO Adar Poonawalla said that the coronavirus vaccine will be distributed initially in India and then the company will look at Covax countries, which are mainly in Africa. Serum Institute of India (SII) is conducting clinical trials of AstraZeneca-Oxford's COVID-19 vaccine candidate in India. Watch the full interview.